Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 9/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.35 |
| ▸ | HTR1A | P08908 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | HTR1D | P28221 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701483 | 0.92 | HTR7 (0.40) | HTR7HTR1ADRD2HTR1DHTR2B | |
| SCHEMBL703365 | 0.89 | TACR1 (0.36) | HTR7HSD11B1HCRTR1NAMPTTACR1 | |
| SCHEMBL3442292 | 0.88 | HTR7 (0.36) | HTR7HTR1ADRD2HTR1DHTR2B | |
| SCHEMBL700048 | 0.82 | ALDH1A1 (0.37) | HTR7DRD2DRD3ALDH1A1ADAMTS5 | |
| SCHEMBL702140 | 0.81 | KMT2A (0.37) | HTR7HTR1AHCRTR1TACR1 | |
| SCHEMBL700842 | 0.80 | HTR7 (0.51) | HTR7HTR1ADRD2HTR1DHTR2B | |
| SCHEMBL701428 | 0.80 | HCRTR1 (0.35) | HTR7HCRTR1ALDH1A1ADAMTS5NAMPT | |
| SCHEMBL700014 | 0.79 | BDKRB1 (0.46) | HSD11B1 | |
| SCHEMBL4296232 | 0.78 | HTR7 (0.38) | HTR7HTR1ADRD2HTR1DHTR2B | |
| SCHEMBL3441798 | 0.77 | KCNQ1 (0.34) | HSD11B1HCRTR1NAMPTTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | claimed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | claimed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264407-A1 | Substituted Sulfonamide Compounds | CNR1, SUCNR1, OPRL1 | HTR7 522/4885HSD11B1 1506/4885HTR1A 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.